Polyacrylamide hydrogel injection in the management of human immunodeficiency virus-related facial lipoatrophy: Results of the LIPOPHILL open-label study

AIDS Research and Human Retroviruses

Volumn 28, Issue 3, 2012, Pages 251-258

  Mole, Bernard ^a   Gillaizeau, Florence ^a,b   Carbonnel, Elisabeth ^c   Pierre, Isabelle ^a   Brazille, Patricia ^d   Grataloup, Christine ^a   Mercier, Sylvie ^c   Duracinsky, Martin ^e   Weiss, Laurence ^a   Piketty, Christophe ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSERM   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^e BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EUTROPHILL; POLYACRYLAMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHEEK; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEL; INFLAMMATION; INJECTION SITE INFECTION; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT ATTITUDE; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RELATIVE; SUBCUTANEOUS NODULE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ACRYLIC RESINS; ADULT; ESTHETICS; FACE; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PARIS; PATIENT SATISFACTION; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84858124245     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0042     Document Type: Article

References (29)

1. Hogg RS, Heath KV, Yip B, et al.: Improved survival among HIV-infected individuals following initiation of anti-retroviral therapy. JAMA 1998;279(6):450-454. (Pubitemid 28082255)
2. Palella FJ, Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338(13):853-860. (Pubitemid 28135961)
3. Mocroft A, Katlama C, Johnson AM, et al.: AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000;356(9226):291-296. (Pubitemid 30459587)
4. Mocroft A, Ledergerber B, Katlama C, et al.: Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362(9377):22-29. (Pubitemid 36835816)
5. Martinez E, Mocroft A, Garcia-Viejo MA, et al.: Risk of lipo-dystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001;357(9256): 592-598. (Pubitemid 32179612)
6. Joly V, Flandre P, Meiffredy V, et al.: Increased risk of li-poatrophy under stavudine in HIV-1-infected patients: Results of a substudy from a comparative trial. AIDS 2002; 16(18):2447-2454. (Pubitemid 35471693)
7. Blanch J, Rousaud A, Martinez E, et al.: Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004;38(10): 1464-1470. (Pubitemid 38668594)
8. Blanch J, Rousaud A, Martinez E, et al.: Impact of lipody-strophy on the quality of life of HIV-1-infected patients. J Acquir Immune Defic Syndr 2002;31(4):404-407. (Pubitemid 35397093)
9. Duran S, Saves M, Spire B, et al.: Failure to maintain long-term adherence to highly active antiretroviral therapy: The role of lipodystrophy. AIDS 2001;15(18):2441-2444. (Pubitemid 34014613)
10. Arribas JR, Pozniak AL, Gallant JE, et al.: Tenofovir dis-oproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47(1):74-78. (Pubitemid 351619372)
11. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292(2):191-201. (Pubitemid 38917996)
12. John M, McKinnon EJ, James IR, et al.: Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003;33(1):29-33. (Pubitemid 36547238)
13. Martin A, Smith DE, Carr A, et al.: Reversibility of lipoa-trophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX Extension Study. AIDS 2004;18(7):1029-1036. (Pubitemid 38591194)
14. McComsey GA, Ward DJ, Hessenthaler SM, et al.: Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study. Clin Infect Dis 2004;38(2):263-270. (Pubitemid 38113036)
15. Milinkovic A, Martinez E, Lopez S, et al.: The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007;12(3):407-415. (Pubitemid 46787986)
16. Moyle GJ, Sabin CA, Cartledge J, et al.: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006;20(16):2043-2050. (Pubitemid 44611057)
17. Tebas P, Zhang J, Hafner R, et al.: Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: Results of ACTG A5110. J Antimicrob Chemother 2009;63(5):998-1005.
18. Valantin MA, Lanoy E, Bentata M, et al.: Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: Results from the 96-week randomized ANRS 108 NoNuke Trial. HIV Med 2008;9(8):625-635.
19. Carey D, Baker D, Petoumenos K, et al.: Poly-L-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up. HIV Med 2009;10(3):163-172.
20. Carey DL, Baker D, Rogers GD, et al.: A randomized, multi-center, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy. JAcquir Immune Defic Syndr 2007;46(5):581-589. (Pubitemid 350191051)
21. Cattelan AM, Bauer U, Trevenzoli M, et al.: Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy. Arch Dermatol 2006;142(3): 329-334.
22. Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, and Molina JM: Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Ac-quir Immune Defic Syndr 2005;38(4):393-398. (Pubitemid 40381548)
23. Mest DR and Humble G: Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience. Dermatol Surg 2006;32(11):1336-1345. (Pubitemid 44691136)
24. Valantin MA, Aubron-Olivier C, Ghosn J, et al.: Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA. AIDS 2003;17(17):2471-2477. (Pubitemid 38393319)
25. Negredo E, Higueras C, Adell X, et al.: Reconstructive treatment for antiretroviral-associated facial lipoatrophy: A prospective study comparing autologous fat and synthetic substances. AIDS Patient Care STDS 2006;20(12):829-837. (Pubitemid 46106070)
26. Guaraldi G, Orlando G, De Fazio D, et al.: Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: A prospective study. Antivir Ther 2005; 10(6):753-759. (Pubitemid 41376855)
27. Negredo E, Puig J, Aldea D, et al.: Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy. AIDS Res Hum Retroviruses 2009;25(4): 451-455.
28. Carr A, Workman C, Smith DE, et al.: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. JAMA 2002;288(2):207-215. (Pubitemid 34755281)
29. Moyle GJ, Baldwin C, Langroudi B, Mandalia S, and Gaz-zard BG: A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Ac-quir Immune Defic Syndr 2003;33(1):22-28. (Pubitemid 36547237)